Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ishares Msci Brazil ETF (EWZ) vs Eli Lilly And Co (LLY) Price & Performance

Ishares Msci Brazil ETFTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Ishares Msci Brazil ETF vs Eli Lilly And Co — how do they compare? Ishares Msci Brazil ETF trades at $33.78, while Eli Lilly And Co trades at $1,220.99 (market cap $1.08T). The key difference: Eli Lilly And Co pays a 0.57% dividend while Ishares Msci Brazil ETF pays none. Which is the better fit depends on your goals.

EWZLLY
Sector
Broad Market / FactorHealth
52-Week High
$41.75$1.24K
52-Week Low
$27.36$639.43
Market Cap
$1.08T
Enterprise Value
$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ishares Msci Brazil ETF

EWZ, the iShares MSCI Brazil ETF, trades at $33.86, down 3.78% in the last session. Technical indicators are bearish overall, with moving averages signaling sell pressure, though oscillators suggest potential for a near-term bounce. Recent news highlights institutional interest, with Empowered Funds LLC taking a $3.06 million position as of August 5, 2026, and Allspring Global Investments increasing its stake significantly in July 2026. The fund offers exposure to Brazilian equities, with a dividend announced for June 2026.

The outlook for EWZ hinges on Brazil's economic trajectory, particularly interest rate cuts and commodity prices. Opportunities exist for value-seeking investors given Brazil's market potential, but risks include U.S. tariff impacts (Reuters, July 16, 2026) and competition from lower-cost ETFs like FLBR, which offers a higher dividend yield (Seeking Alpha, July 16, 2026).

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.

Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ishares Msci Brazil ETF

EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.

Read more on EWZ

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY